Literature DB >> 912922

A rapid, sensitive and specific radioimmunoassay for methotrexate.

J W Paxton, F J Rowell.   

Abstract

A rapid, sensitive, radioimmunoassay for methotrexate has been developed using tritiated methotrexate and an antiserum raised in rabbits against the immunogen, bovine serum albumin containing 34 methotrexate residues per protein molecule. Separation of bound and free drug was attained using donkey anti-rabbit precipitating serum. The method can accurately measure as little as 50 fmol methotrexate in capillary blood samples and is not interfered with by vast excesses of natural folates nor citrovorum rescue factor. The method can handle 30 samples per day with the results available after 6 h. This makes it suitable for monitoring serum methotrexate levels after high dose therapy when a result is required within 24 h to provide helpful information regarding impending toxicity and the need for extended citrovorum rescue factor or maintenance of urinary pH.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 912922     DOI: 10.1016/0009-8981(77)90151-6

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  4 in total

1.  An indication of possible impending toxicity during moderately high dose methotrexate infusions.

Authors:  J W Paxton; E J Stephens; H F Wood
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

2.  Enhancement of methotrexate absorption by subdivision of dose.

Authors:  W H Steele; J F Stuart; J R Lawrence; C A McNeill; W E Sneader; B Whiting; K C Calman; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Bioavailability of methotrexate: implications for clinical use.

Authors:  J F Stuart; K C Calman; J Watters; J Paxton; B Whiting; J R Lawrence; W H Steele; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Serum, tear and salivary concentrations of methotrexate in man.

Authors:  W H Steele; J F Stuart; B Whiting; J R Lawrence; K C Calman; J G McVie; G M Baird
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.